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Abstract. Bronchiolitis is a rare condition mainly affecting the 
intralobular conducting and transitional small airways. The 
present study describes a case of severe airflow limitation in a 
patient with ulcerative colitis who developed toxic epidermal 
necrolysis following mesalazine therapy. Forced expiratory 
volume in one second was decreased and a flow-volume 
curve showed airf low limitation, but the single-breath 
diffusing capacity of the lung for carbon monoxide (DLCO) 
and DLCO divided by alveolar volume (DLCO/VA) were not 
decreased. This rare clinical condition should be consid-
ered as a differential diagnosis for subjects presenting with 
sub‑acutely developed airflow obstruction if the findings in 
chest computed tomography scans demonstrate hyperinfla-
tion but few low-attenuation areas. Relatively well-preserved 
DLCO and DLCO/VA provide a clue to establishing the correct 
diagnosis.
Introduction
Obstructive bronchiolitis (OB) is a rare disease and affects 
small airways of the lung and is associated with restriction of 
the airways (1). OB must be considered as a potential diagnosis 
in patients with obstructive respiratory impairment, the most 
common symptom of which is dyspnea (1). This inflamma-
tory process is associated with various conditions, including 
ulcerative colitis (UC) and toxic epidermal necrolysis (TEN). 
UC is a chronic relapsing inflammatory bowel disease of 
uncertain etiology. UC may occur at any age, but is most 
commonly diagnosed in late adolescence or early adult-
hood (2). The incidence of UC has increased worldwide over 
recent decades, particularly in developing nations (2). Typical 
symptoms of UC include, bloody diarrhea, abdominal pain, 
urinary urgency and tenesmus (2). TEN is acute drug-induced 
condition associated with severe blistering, skin peeling and 
multi-organ damage, and is classed in the same spectrum of 
diseases as Stevens-Johnson syndrome (3,4). TEN symptoms 
typically resemble severe scalding, with ≥30% top layer of skin 
detaching from the lower dermis (3). OB must be considered 
as a differential diagnosis in patients with obstructive respira-
tory impairment (4). In the case reported in the present study 
a patient with ulcerative colitis (UC), who developed toxic 
epidermal necrolysis (TEN) (5) following mesalazine therapy, 
presented with severe airflow limitation.
Case report
A 53-year-old male was received at the Mito Medical Center 
(Mito, Japan) with a two-month history of exertional dyspnea, 
which was not accompanied by a dry cough, fever, chill or 
chest pain. There was no history of antecedent respiratory 
tract infection. The patient had a 15-pack-year smoking 
history, having stopped 20 years previously, and no allergies. 
There was no recognized history of exposure to fumes or 
mineral dusts. The patient had been diagnosed as having UC 
25 years previously and was given mesalazine therapy, since 
therapy with prednisolone had not led to any improvement in 
the UC. Following an increase in the dose of mesalazine to 
2,250 mg/day, the patient developed a high fever (>38˚C) and 
a large number of red papules and erythemas. The eruptions 
rapidly spread to the whole body and changed to erythroderma 
in one week. The eruptions additionally caused blistering, 
epidermolysis and erosion of >10% of the body's surfaces a 
few days later. No findings suggested staphylococcal scalded 
skin syndrome. Based on the skin symptoms and clinical 
course, the patient was diagnosed with TEN due to the 
mesalazine. The patient received several courses of steroid 
pulse therapy with methylprednisolone and plasma exchange 
therapy. The patient recovered from the TEN as a result of 
these intensive therapies, although scars and pigmentation in 
the trunk and extremities remained. Informed consent was 
obtained from the patient.
On admission, the respiratory rate of the patient was 
18 beats/min and his breath sound was diminished, without 
any expiratory rhonchi. Clubbing was absent. The forced 
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expiratory volume in one second (FEV1.0) was 0.77 liters 
(36.4% of predicted) and the forced vital capacity was 
2.97 liters (80.1% of predicted). A flow‑volume curve showed 
airflow limitation (Fig. 1). The residual volume was 2.57 liters 
(153% of predicted), the functional residual capacity was 
3.97 liters (97% of predicted) and the single‑breath diffusing 
capacity of the lung for carbon monoxide (DLCO) and DLCO 
divided by alveolar volume (DLCO/VA) were 105 and 93% 
of the predicted values, respectively. A chest radiograph 
showed scarce hyperinflation. No improvement in the FEV1.0 
was observed following inhalation of a β-stimulant. A chest 
computed tomography (CT) scan showed only a small number 
of low-attenuation areas and bullae and demonstrated central 
bronchiectasis and a mosaic pattern, which intensified on 
expiration (Fig. 2). These findings were not consistent with 
pulmonary emphysema as a cause of severe airflow limitation. 
The results, including a respiratory function test and radio-
logical examination, were highly suggestive of OB. Inhalation 
of corticosteroid and anticholinergic agents, oral theophylline 
and inhaled corticosteroid were not effective in this patient. 
Respiratory rehabilitation and long-acting β2-agonist/inhaled 
corticosteroid appeared to cause a slight reduction in his exer-
tional dyspnea; however, the potential role of these therapies 
requires further examination. The patient did not recover 
completely. Twenty-six months following disease onset the 
patient remained alive and was discharged from the outpa-
tient clinic.
Discussion
OB is an inflammatory process that primarily affects small 
conducting airways of the lungs, resulting in differing 
levels of airflow limitation (2). This inflammatory process 
is associated with numerous conditions, including UC (5-7), 
bullous skin disease (8), Stevens-Johnson syndrome (9-14), 
graft versus host disease following a lung or bone marrow 
transplant (15-18) and certain drugs (1,6). The current patient 
was a middle-aged ex-smoker who complained of sub-acutely 
developed exertional dyspnea. Early-onset chronic obstruc-
tive pulmonary disease was initially suspected from the 
patient's symptoms and severe irreversible airway limita-
tion; however, the chest CT scan was not consistent with 
smoking-induced centrilobular emphysema in this case, 
although the diagnosis of panlobular emphysema could not 
be refuted. It is generally accepted that decreases in DLCO 
and DLCO/VA are useful indicators of pulmonary emphy-
sema (19,20); therefore, these parameters were evaluated, but 
no decreases were found despite severe irreversible airflow 
limitation. A mosaic pattern and bronchiectasis have been 
reported to be the typical findings in OB, although there 
have been cases demonstrating only diffuse hyperinflation, 
bronchial wall thickening and bronchiectasis, or even normal 
findings on a CT scan (21,22). In the present patient, a chest 
CT scan showed bronchiectasis and thickening of the walls 
of the central bronchi in both lungs.
In the present case, the patient had UC and had received 
plasma exchange for the treatment of TEN, which are known 
causes of OB (1,4-6,23). TEN and Stevens-Johnson syndrome 
are defined as drug-related dermatopathies on the same 
spectrum (4), and a case of severe OB associated with TEN 
has been previously reported (24). We speculated that the 
OB in the present case may have developed as a result of an 
impairment of the respiratory mucous membrane, as observed 
in Stevens-Johnson syndrome, and that there was a high prob-
ability that this severe airflow limitation had an association 
with the development of TEN due to mesalazine therapy. 
Thus, if drugs were directly responsible for the development 
of OB in this patient, mesalazine would be a highly probable 
candidate.
Regarding adverse events due to mesalazine, certain 
pulmonary toxicities have already been reported (5,6,25). 
Notably, two previous reports have described OB in patients 
with UC receiving mesalazine (6,7), as observed in the 
present case; however, the cause and precise mechanism 
of OB resulting from mesalazine treatment is not currently 
known.
Pathological examination of the affected bronchioles is 
important to the diagnosis of OB (1,26). The narrowing of 
Figure 1. Flow-volume curve at the time of presentation to the hospital with 
dyspnea on effort. *Predicted curve; **measured curve.
Figure 2. Slices (A) and (B) of chest computed tomography scan display bron-
chiectasis and thickening of the walls of the central bronchi in both lungs.
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bronchioles by necrotic and fibrotic changes are the main 
pathogeneses of OB (1,26); however, the majority of the patients 
with OB have exertional dyspnea with airflow limitation and it 
may, therefore, be challenging to obtain sufficient specimens 
from these individuals. The present patient declined a surgical 
approach, and the lung specimen could not be obtained.
In conclusion, the present study describes a case of OB in 
a patient with UC who developed TEN following mesalazine 
therapy. This rare clinical combination should be considered 
as a differential diagnosis, even for middle-aged, ex-smoking 
subjects presenting with sub-acutely developed airflow 
obstruction, if the findings in the chest CT scan demonstrate 
hyperinflation but few low-attenuation areas. Relatively 
well-preserved DLCO and DLCO/VA can provide a clue to 
establishing a correct diagnosis.
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